BDBM513960 US11059823, Example 2

SMILES N#CC[C@H]1CC[C@H](n2c(-c3c[nH]cn3)nc3cnc4[nH]ccc4c32)CC1

InChI Key InChIKey=GJBSQXREQHZZIS-UHFFFAOYSA-N

Data  4 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 4 hits for monomerid = 513960   

TargetTyrosine-protein kinase JAK1(Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 513960BDBM513960(US11059823, Example 2)
Affinity DataIC50: 0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/2/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 513960BDBM513960(US11059823, Example 2)
Affinity DataIC50: 1nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/2/2022
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 513960BDBM513960(US11059823, Example 2)
Affinity DataIC50: 1.5nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/2/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Janssen Pharmaceutica

US Patent
LigandChemical structure of BindingDB Monomer ID 513960BDBM513960(US11059823, Example 2)
Affinity DataIC50: 33.9nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/2/2022
Entry Details
US Patent